Association between glucose to lymphocyte ratio and prognosis in patients with solid tumors

Front Immunol. 2024 Dec 6:15:1454393. doi: 10.3389/fimmu.2024.1454393. eCollection 2024.

Abstract

Background: Glucose-to-lymphocyte ratio (GLR) plays an important role in the prognosis of various tumors. The aim of this study was to comprehensively evaluate the prognostic value of GLR in solid tumors through the meta-analysis.

Methods: A comprehensive search of eligible studies was performed by scrutinizing the Pubmed, Embase and Web of science databases until May 30, 2024. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to evaluate overall survival (OS), disease-free survival (DFS) and recurrence free survival (RFS).

Results: A total of 22 studies from 14 articles involving 9472 patients were included in the study. The pooled analysis showed that cancer patients with high GLR was significantly associated with unfavorable OS (HR:1.48,95% CI:1.34-1.63) and DFS/RFS (HR:2.20,95% CI:1.66-2.92). Subgroup analysis further showed that high GLR had better predictive value in liver cancer (HR:2.66, 95%CI:1.80-3.93), breast cancer (HR:2.13, 95%CI:1.10-4.13) and pancreatic cancer (HR:1.92, 95%CI:1.30-2.84).

Conclusions: GLR can be used as an effective prognostic marker in patients with solid tumors.

Keywords: glucose-to-lymphocyte ratio; meta-analysis; prognosis; survival; tumor.

Publication types

  • Meta-Analysis

MeSH terms

  • Biomarkers, Tumor / blood
  • Glucose / metabolism
  • Humans
  • Lymphocyte Count
  • Lymphocytes* / immunology
  • Neoplasms* / blood
  • Neoplasms* / diagnosis
  • Neoplasms* / immunology
  • Neoplasms* / mortality
  • Prognosis

Substances

  • Biomarkers, Tumor
  • Glucose

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.